

TICK-BORNE ENCEPHALITIS (TBE) VACCINE

Katherine Poehling, MD, MPH
Chair, ACIP TBE Vaccine Work Group
February 23, 2022

Background

- Food and Drug Administration (FDA) approved a TBE vaccine (manufactured by Pfizer as TICOVAC) in August 2021
- No TBE vaccine previously licensed in the United States
- No existing ACIP TBE vaccine recommendations
- TBE Vaccine Work Group formed in September 2020 to discuss use of TBE vaccine in U.S. persons traveling abroad and laboratory workers

TBE Vaccine Work Group members and participants

ACIP

Katherine Poehling (Chair)

Wilbur Chen

ACIP liaisons

David Shlim, ISTM

Mark Sawyer, AAP

Technical advisors (cont'd)

Steven Schofield, CATMAT

Bryan Schumacher, DOD

Mary Wilson, Univ Calif SFO

CDC participants (cont'd)

Stacey Martin, DVBD

Michael McNeil, DHQP

Rebecca Morgan, Consultant

CDC Lead

Susan Hills, DVBD

Technical advisors

Alan Barrett, Univ Texas Galveston

Lin Chen, Mount Auburn Hosp

CDC participants

Grace Appiah, DGMQ

Erin Staples, DVBD

Steve Waterman, DVBD

Ex Officio

Rodolfo (Rudy) Alarcon, NIH

Anthony Marfin, PATH

Bruce McClenathan, DOD

Doug Campos-Outcalt, Consultant

Susan Chu, GID

ACIP Secretariat

Jessica MacNeil, NCIRD

Ihid Carneiro Leao, FDA

Kayvon Modjarrad, DOD

Caitlin Cossaboom, DHCPP

Melinda Wharton, NCIRD

Overview of previous Work Group presentations to ACIP

- October 2020
 - Background on TBE disease and vaccines
 - Summary of Pfizer's TBE vaccine
- February 2021
 - TBE epidemiology in endemic areas
 - TBE among U.S. travelers and laboratory workers
- September 2021
 - Immunogenicity and safety of Pfizer's TBE vaccine
- January 2022
 - Evidence to Recommendations framework

Overview of today's session

- Brief review of TBE and TBE vaccine
- Review of considerations for use of TBE vaccine and proposed recommendations for laboratory workers
- Review of considerations for use of TBE vaccine and proposed recommendations for persons who travel abroad